ACST | Acasti Pharma (NASDAQ:ACST) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Acasti Pharma (NASDAQ:ACST) from a buy rating to a hold rating in a research note issued to investors on Monday, reports.According to Zacks, “Acasti Pharma a biopharmaceutical company.It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies.[…]Transcript Daily